- Investor's Business Daily•yesterday
Regeneron expects to top Amgen's recent heart-drug study in a team-up with Sanofi.
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Investor's Business Daily•2 days ago
Alnylam's fitusiran will pull in $989 million in 2025, but won't launch until 2020 amid competition with Biogen spinoff Bioverativ.
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||52.00 x 300|
|Ask||52.10 x 200|
|Day's Range||51.70 - 53.58|
|52 Week Range||31.38 - 80.11|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-10.82|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|